

**SUBCOMMITTEE ON OVERSIGHT AND INVESTIGATIONS
DOCUMENT INDEX**

APRIL 16, 2013

**"A Continuing Investigation into the Fungal Meningitis Outbreak
and Whether It Could Have Been Prevented"**

Exhibit Number	Document
1	FDA Timeline of Interactions with NECC and Ameridose
2	April 27, 2004 email
3	May 27, 2004 email
4	January 27, 2006 email
5	March 2, 2006 email
6	February 22, 2007 email
7	September 14, 2009 email
8	September 28, 2009 email
9	FDA Consumer Complaint/Injury Report (received September 17, 2009)
10	2006 FDA Warning Letter to NECC
11	FDA Adverse Event Report (received December 11, 2007)
12	December 12, 2007 email
13	FDA Memorandum, January 9, 2007
14	FDA Consumer Complaint/Injury Report (dated October 9, 2008)
15	June 25, 2008 email
16	January 9, 2007 email
17	December 5, 2006 email
18	September 26, 2008 email
19	October 1, 2008 email
20	October 22, 2008 email
21	November 4, 2008 email
22	2013 FDA Warning Letter to Medi-Fare Drug & Home Health Center, Inc.
23	FDA Memo of Meeting, October 15, 2008
24	FDA Call Notes dated May 24, 2011
25	September 14, 2010 email
26	May 21, 2007 email
27	September 5, 2007 email
28	January 24, 2009 email
29	Establishment Inspection Report, Ameridose LLC, dated August 6, 2008
30	September 2, 2009 email
31	December 7, 2009 email
32	August 17, 2010 email
33	Complaint Against Ameridose, LLC re: Pre-Mixed Nicardipine Injection

Exhibit Number	Document
	Products, dated June 30, 2010
34	July 19, 2010 email
35	July 14, 2010 email
36	July 19, 2010 email
37	July 6, 2011 email
38	September 16, 2011 email
39	October 24, 2011 email
40	FDA Adverse Event Report (received November 17, 2011)
41	FDA Adverse Event Report (received January 24, 2012)
42	FDA Adverse Event Report (received January 25, 2012)
43	FDA Adverse Event Report (received March 12, 2012)
44	FDA Adverse Event Report (received March 23, 2012)
45	FDA Memorandum, Office of the Commissioner Meeting, May 12, 2009
46	July 29, 2009 email
47	
48	CRS Report, R40503, dated October 17, 2012
49	May 17, 2012 email
50	August 10, 2006 email
51	August 10, 2006 email
52	August 28, 2006 email
53	Compounded Human Drugs Briefing, January 12, 2007
54	FDA Memorandum dated April 1, 2011
55	January 19, 2007 email
56	CDER/ORR Compounding Pharmacy Compliance Policy dated September 17, 2012
57	FDA Memorandum dated February 24, 2012
58	FDA Memorandum, Office of the Commissioner Meeting, May 3, 2002
59	FDA Memorandum dated October 2, 2012
60	July 6, 2011 email
61	American Pharmaceutical Association, Pharmacy Compounding: FDA Regulatory Policy, March 30, 2004 slide presentation
62	Rep. Markey report, "Compounding Pharmacies Compounding Risk, October 29, 2012
63	July 17, 2012 email
64	IACP Draft Comments dated July 30, 2002 (IACP001662-1674)
65	Department of Health and Human Services Memorandum dated October 4, 2011
66	Department of Health and Human Services Memorandum dated August 28, 2012
67	July 5, 2012 email
68	FDA Memorandum dated November 1, 2012